A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rontalizumab (rhuMAb IFNalpha) in Patients With Moderately to Severely Active Systemic Lupus Erythematosus.

Trial Profile

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rontalizumab (rhuMAb IFNalpha) in Patients With Moderately to Severely Active Systemic Lupus Erythematosus.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2016

At a glance

  • Drugs Rontalizumab (Primary) ; Rontalizumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Acronyms ROSE
  • Sponsors Genentech
  • Most Recent Events

    • 10 Aug 2016 Number of treatment arms changed from 2 to 5.
    • 02 Jun 2015 Results published in the Annals of the Rheumatic Diseases.
    • 29 Jan 2013 Planned End Date changed from 1 Sep 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top